Table 4.
Grade 3 or greater adverse events related to study therapy by causality.
| Adverse Events | Related to trabectedin | Related to nivolumab | Related to talimogene laherparepvec | |||
|---|---|---|---|---|---|---|
| 3 | 4 | 3 | 4 | 3 | 4 | |
| Blood and lymphatic system disorders | ||||||
| Anemia | 8 (16%) | |||||
| General disorders and administration site conditions | ||||||
| Fatigue | 2 (4%) | |||||
| Pain at tumor site | 1 (2%) | |||||
| Investigations | ||||||
| Alanine aminotransferase increased | 9 (18%) | |||||
| Aspartate aminotransferase increased | 3 (6%) | |||||
| Neutrophil count decreased | 7 (14%) | 1 (2%) | ||||
| Platelet count decreased | 4 (8%) | 1 (2%) | ||||
| CPK increased | 1 (2%) | |||||
| GGT increased | 1 (2%) | |||||
| Ejection fraction decreased | 1 (2%) | |||||
| T3 decreased | 1 (2%) | |||||
| Metabolism and nutrition disorders | ||||||
| Dehydration | 1 (2%) | |||||
| Hyponatremia | 1 (2%) | |||||